This Article Full Text (PDF) All Versions of this Article: 1352458508099142v1 15/3/371    most recent References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Feys, P Articles by Helsen, W. Search for Related Content PubMed PubMed Citation Articles by Feys, P Articles by Helsen, W. Social Bookmarking                         What's this?

The effect of levetiracetam on tremor severity and functionality in patients with multiple sclerosis

Department of Biomedical Kinesiology, Katholieke Universiteit Leuven, Leuven, Belgium; REVAL Research Institute, and BIOMED PHL/Uhasselt, Belgium

MB D’hooghe

G Nagels

National MS Centre, Melsbroek, Belgium; University of Antwerp, Biomedical Sciences Department, Antwerp, Belgium

WF Helsen

Department of Biomedical Kinesiology, Katholieke Universiteit Leuven, Leuven, Belgium

Background

Multiple sclerosis (MS) intention tremor is a disabling symptom, which is difficult to treat.

Objectives

To investigate the effects of levetiracetam, an antiepileptic drug, on tremor severity and related functionality in MS.

Methods

A randomized, double-blind, placebo-controlled, cross-over study examined the effects of 6 weeks of oral levetiracetam administration (starting dose = 250 mg/day, maximal dose = 2000 mg/day) in 18 MS patients with disabling intention tremor. Primary outcome was Fahn’s Tremor Rating Scale (FTRS) A&B. Secondary outcome measures were the nine-hole peg test, patient’s opinion rated with the visual analog scale, FTRS C, and an activities of daily life questionnaire and validated tremor indexes derived during the performance of a digitized spiral drawing task and a wrist step-tracking task. Repeated measures analysis of variance and Friedman tests were applied.

Results

In all, 14 patients completed the trial. Maximal dose intake ranged from 1000 to most commonly 2000 mg, depending on patients’ tolerance level. No significant effects of levetiracetam were found for any outcome measure. Further analyses on subgroups with different tremor severity showed no differential effects. Eight patients reported adverse events such as fatigue and stomach ache.

Conclusions

Levetiracetam intake of 2000 mg/day did not affect tremor severity or functionality in patients with MS.

Key Words: intention tremor • levetiracetam • Multiple sclerosis • symptomatic treatment

This version was published on March 1, 2009

Multiple Sclerosis, Vol. 15, No. 3, 371-378 (2009)
DOI: 10.1177/1352458508099142


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?